South Asia Journal Watch: 22 November 2026

South Asia Journal Watch

South Asia Journal Watch

South Asia Journal Watch: 22 November 2026

Microbiology, infectious disease, AMR and infection-control papers from India and South Asia added to PubMed on 20 to 22 November 2026 and not covered in earlier issues.

Lead articles

Lymphatic filariasis · Retrospective cohort · iScience

Determinants of progression of filarial lymphedema in a clinic-based cohort: Implications for global elimination

iScience · doi:10.1016/j.isci.2026.118171 · PubMed 43061521

What
A study of the long-term clinical course of filarial lower-limb lymphoedema and the factors associated with change in limb volume.
Design
Retrospective cohort of 110 adult patients with filarial lower-limb lymphoedema in Puducherry, India, followed for a median of nine years (ICMR National Institute for Vector Control Research, Puducherry). Limb volume change was objectively quantified, and determinants of progression were assessed by multivariable regression.
Key findings
Nearly half of the cohort (46.4%) showed no volumetric progression over follow-up. Recurrent adenolymphangitis episodes and baseline hypertension correlated with the severity of progression. In multivariable regression, strict adherence to home-based morbidity management and disability prevention (MMDP) self-care practices was the primary independent predictor of halted or reduced limb volume change. The authors concluded that sustained adherence to simple self-care interventions can mitigate chronic lymphoedema.
Limitations
Retrospective, single clinic-based cohort; the abstract does not report effect sizes for the predictors or describe how self-care adherence was measured, and the findings may not apply to patients outside clinic follow-up.
Relevance to South Asia
Lymphatic filariasis remains endemic in parts of India, where MMDP is a core component of the elimination programme; this cohort provides long-term outcome data from an Indian clinical setting.

Vaccines · Systematic review and meta-analysis · Human Vaccines & Immunotherapeutics

Cross-protective immune responses to pneumococcal serotype 6A following vaccination with 6B-containing pneumococcal conjugate vaccines: A systematic review and meta-analysis

Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2762621 · PubMed 43059099

What
A systematic review and meta-analysis of serotype 6A-specific immune responses after vaccination with pneumococcal conjugate vaccines (PCVs) containing serotype 6B, which may give cross-protection against 6A.
Design
Databases were searched for studies reporting IgG geometric mean concentrations (GMCs), proportions achieving IgG ≥ 0.35 µg/mL, and opsonophagocytic activity (OPA) titres. Forty-three studies met the inclusion criteria and eight contributed quantitative data (PROSPERO CRD420251134118). The authors are based in Mumbai and Delhi.
Key findings
Overall, 6B-containing vaccines elicited measurable cross-reactive IgG and functional responses against serotype 6A. Booster-containing 3 + 1 schedules showed numerically higher responses than 3 + 0 schedules, with pooled IgG GMCs of 1.63 vs. 0.59 µg/mL, proportions achieving IgG ≥ 0.35 µg/mL of 92.78% vs. 65.38%, and OPA GMTs of 984.6 vs. 169.2, respectively.
Limitations
Only eight of the 43 included studies contributed quantitative data; outcomes are immunogenicity measures rather than clinical protection, and the abstract does not report heterogeneity or a formal statistical comparison between schedules.
Relevance to South Asia
The authors note that India bears a pneumococcal disease burden, with serogroup 6 contributing to invasive pneumococcal disease, acute otitis media and nasopharyngeal carriage.

More from the journals

Antimicrobial resistance and novel agents

Parasitic, vector-borne and zoonotic infections

Mycology

Other: environmental microbiology

Items are summaries of published abstracts and are not clinical advice. Readers should consult the original article. Figures are quoted as reported in each abstract.

Leave a Reply

Your email address will not be published. Required fields are marked *